Myriad Genetics retained its monopoly on a lucrative genetic test for breast cancer risk when a federal appeals court recently upheld the company’s patents on two human genes — and the validity of gene patents in general.
Enlarge This Image
But it is only a matter of time before the company’s business faces severe challenges, some experts say, because that $3,340 test is technologically outmoded, incomplete and too costly.
Wednesday, August 24, 2011
Its #Gene #Patents Upheld, Myriad Genetics Moves to Protect Its Secrets - NYTimes.com: